A5031294106- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Genetic factors in colorectal cancer
- Lung Cancer Treatments and Mutations
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Chronic Lymphocytic Leukemia Research
- Radiomics and Machine Learning in Medical Imaging
- Cancer, Lipids, and Metabolism
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Treatment and Pharmacology
- Lipoproteins and Cardiovascular Health
- Cancer, Stress, Anesthesia, and Immune Response
- Prostate Cancer Treatment and Research
- PARP inhibition in cancer therapy
- Multiple and Secondary Primary Cancers
- Cancer-related Molecular Pathways
- Inflammatory Biomarkers in Disease Prognosis
- Viral-associated cancers and disorders
- Colorectal Cancer Surgical Treatments
- Radiopharmaceutical Chemistry and Applications
- Peptidase Inhibition and Analysis
- Advanced Breast Cancer Therapies
- Neuropeptides and Animal Physiology
Personalis (United States)
2024-2025
Tempus Labs (United States)
2021-2023
University of Florida
2013-2017
University of Kentucky
2017
Brown University
2017
Promising single-agent activity from sotorasib and adagrasib in KRASG12C-mutant tumors has provided clinical evidence of effective KRAS signaling inhibition. However, comprehensive analysis KRAS-variant prevalence, genomic alterations, the relationship between immuno-oncology biomarkers is lacking.Retrospective deidentified records 79,004 patients with various cancers who underwent next-generation sequencing was performed. Fisher's exact test evaluated association cancer subtypes variants....
PURPOSE Biliary tract cancers (BTCs) are aggressive that carry a poor prognosis. An enhanced understanding of the immune landscape anatomically and molecularly defined subsets BTC may improve patient selection for immunotherapy inform immune-based combination treatment strategies. METHODS We analyzed deidentified clinical, genomic, transcriptomic data from Tempus database to determine mutational frequency clustering across three major subtypes (intrahepatic cholangiocarcinoma [IHC],...
Abstract Circulating tumor DNA (ctDNA) is a non-invasive biomarker increasingly used to detect residual or recurrent disease and monitor patient response therapy. However, there need for more sensitive tests that can achieve earlier detection of disease. The NeXT Personal® Dx (NPDx) ctDNA MRD test uses paired normal whole genome sequencing (WGS) design bespoke panel up ∼1800 variants relies on advanced noise suppression ultrasensitive down ∼1 part per million (PPM) (1x10-6 fraction) with...
Cohort studies report associations between statin use and improved survival in patients with cancer. We used pharmacoepidemiologic methods to evaluate the of cancer who received statins alone or ostensibly synergistic drug combinations.Patients were diagnosed from 2010 2013 identified a large health care claims database. The rate all-cause death up 1 year after diagnosis was compared by Cox proportional hazard regression. Sensitivity analyses included age stratification, type intensity,...
Immune checkpoint inhibition reactivates the immune response against cancer cells in multiple tissue types and has been shown to induce durable responses. However, for patients with autoimmune disorders, their conditions can worsen this reactivation. We sought identify, among lung renal cancer, how many harbor a comorbid condition may be at risk of worsening while on inhibitors such as nivolumab pembrolizumab.An administrative health care claims database, Truven MarketScan, was used identify...
Background . In patients with hepatocellular carcinoma, selection criteria for transarterial hepatic selective internal radiotherapy are imprecise. Additionally, radiographic parameters to predict outcome of have not been fully characterized. Patients and methods Computed tomography (CT) scans 23 unresectable primary carcinoma before after yttrium-90 microspheres were retrospectively reviewed. Selected evaluated correlated progression-free survival overall survival. Response treatment was...
Glioblastoma (GBM) is a malignant central nervous system neoplasm that remains largely incurable. Limited treatment options currently exist after disease progression on standard-of-care first-line therapy. However, repurposing the use of approved therapies in patients with potentially targetable genomic alterations continues to be an emerging area interest. This report presents first description patient isocitrate dehydrogenase wild-type GBM underlying RET amplification who demonstrated...
3067 Background: The KEYNOTE-177 trial demonstrated pembrolizumab’s superiority over first-line chemotherapy in patients with MSI-H/dMMR mCRC. However, a subgroup analysis, KRAS or NRAS mutations did not show the same favorable PFS benefit PD-1 blockade therapy (HR 1,19; CI 0.68-2,07). impact of RAS on immunologic characteristics TME CRC has been well characterized. Methods: A retrospective review deidentified records tumors was conducted using next-generation sequencing data (Tempus |xT...
4023 Background: Biliary tract cancers (BTC) are increasingly subtyped by molecular alterations, but little is known about the relationship between gain-of-function mutations and RNA transcript expression of immune-related pathways. Methods: A sample retrospective, clinicogenomic transcriptomic data from de-identified records patients with BTC in Tempus database was selected. We then investigated mutational landscape signatures different anatomic genomic subtypes. Results: The cohort...
176 Background: ERBB2 is a rapidly emerging therapeutic target for subset of colorectal cancer (CRC) harboring oncogenic alterations in this gene. Oncogenic ERBB3 mutations have been reported various cancers including CRC, but little known about its functional impact. Optimal targeting pathway requires understanding the genomic context which somatic ERBB2/3 ( ERBB2/3-alt) occur real-world CRC population. Methods: We analyzed 7,688 de-identified records from patients that underwent next...
588 Background: Neoadjuvant THP may become a new standard for pts with early stage HER2+ BC pending results of large ongoing trials. Although ctDNA persistence in the (neo)adjuvant setting is associated elevated risk distant recurrence, prevalence and dynamics are unknown. Methods: On single-arm phase II DAPHNe trial, II-III received 12 weeks neoadjuvant THP, followed by surgery adjuvant systemic therapy (tx) per physicians’ discretion (with no further chemotherapy case pCR). Plasma samples...
Vascular endothelial growth factor (VEGF) and related pathway elements are critically important in the pathogenesis, growth, development of solid tumors. Inhibiting VEGF signaling is being investigated as a therapeutic strategy for cancer, either by blockade ligand binding or inhibition receptor. Aflibercept inhibitor that has been approved US Food Drug Administration treatment macular degeneration metastatic colorectal cancer (mCRC). A search PubMed MEDLINE from January 2000 to August 2013...
Abstract Background: HER2 activating mutations occur in 2-5% of metastatic breast cancer (MBC) patients. These cluster the kinase domains and at amino acids 309-310 extracellular domain. The MutHER, SUMMIT, PlasmaMATCH clinical trials have shown neratinib monotherapy or plus fulvestrant combination produce benefit 28% to 46% HER2-mutated MBC patients, but median progression-free survival was only 3.6 5.4 months. In order improve knowledge outcomes for patients with MBC, we compared...
e19009 Background: Bevacizumab has increased survival in NSCLC patients (pts) when added to standard chemotherapy. However, whether radiographic features at baseline and/or post-treatment can predict benefit from addition of anti-angiogenic therapy chemotherapy remains unknown. In addition, the impact VEGF-targeted on CT parameters is not fully characterized. Methods: A retrospective review was performed using scans pts enrolled into a prospective phase II clinical trial pemetrexed,...
e13030 Background: In patients (pts) with non-small cell lung cancer (NSCLC), it is unknown whether pts bone metastases are predisposed to the development of brain metastases. The impact bevacizumab (Bev) on and not fully characterized. Methods: Retrospective review stage IV NSCLC without metastasis at diagnosis was undertaken. primary endpoint determine predictive Secondary endpoints involved proportion who developed and/or while being treated Bev. Data were analyzed using competing risks...
151 Background: The use of PARP inhibitors (PARPi) may trigger synthetic lethality tumor cells in the context deficient homologous recombination repair (HRR). Approximately 10-20% patients with prostate cancer harbor mutations HRR pathway, but HRR-associated do not consistently predict response to PARPi. Considering alternative methods define Homologous Recombination Deficiency (HRD)—the inability double strand breaks—may aid identifying additional tumors that are sensitive Here, we evaluate...
3066 Background: The BRAF V600E mutation is associated with the hypermethylator phenotype CIMP, which can also lead to MSI-H phenotype. and MSI-H/dMMR status seem be biologically intertwined; however, impact of coexisting mutations on TME immunometabolomic features CRC tumors not well characterized. Methods: A retrospective review deidentified records patients was conducted using next-generation sequencing data (Tempus |xT assay: DNA-seq 595-648 genes at 500x coverage, full transcriptome...
104 Background: Molecular changes and associated acquired resistance of rectal tumors following chemoradiotherapy (CRT) have not been well studied. We aimed to examine CRT-induced molecular prognostic associations in cancer patients (pts) undergoing preoperative CRT followed by surgery. Methods: A paired analysis using pre-CRT biopsies the corresponding post-CRT resected tissues surgery was performed. Pre- tumor samples underwent next-generation sequencing (NGS) Tempus xT assay, which...
3127 Background: Sotorasib has shown promising activity in cancer patients (pts) specifically harboring the KRAS G12C mutation. Response rates vary significantly by tumor type, suggesting pathogenesis may be cancer-type-dependent. Methods: We retrospectively analyzed de-identified records of 79,004 pts with various types that underwent Tempus xT and xF next generation sequencing assays. Fisher’s exact test was used to analyze association between subtypes variants. Logistic regression study...